The challenges of managing cancer related venous thromboembolism in the palliative care setting

Postgraduate Medical Journal

Volumn 83, Issue 985, 2007, Pages 671-674

  Noble, S ^a  

^a ROYAL GWENT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; D DIMER; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; WARFARIN;

ANTICOAGULATION; BLEEDING; CANCER PATIENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; PALLIATIVE THERAPY; QUALITY OF LIFE; REVIEW; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; NEOPLASMS; PALLIATIVE CARE; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 36749028887     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2007.061622     Document Type: Review

References (32)

1. Trousseau A. Phlegmasia alba dolens. In: Clinique Medicale d'Hotel-Dieu de Paris, vol 3. Paris: JB Balliere et Fils, 1865:654-812.
2. Bick RL. Alterations of haemostasis with malignancy. Semin Thromb Hemost 1978;5:1-26.
3. Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol 1999;11:105-10.
4. Ambrus JL, Ambrus CM, Pickren JW. Causes of death in cancer patients. J Med 1975;6:61-4.
5. Sproul EE. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938;34:566-85.
6. Lee AY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 2005;128:291-302.
7. Maltoni M, Caraceni A, Brunelli C, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005;23:6240-8.
8. Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ 2000;320:469-73.
9. Johnson MJ, Sherry K. How do palliative physicians manage venous thromboembolism? Palliat Med 1997;11:462-8.
10. Wolf RA. Are patients with cancer receiving adequate thromboprophylaxis? Results from FRONTLINE. Cancer Treat Rev 2003;29(Suppl 2):7-9.
11. Kirwan CC. Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey. BMJ 2003;327:597-8.
12. Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol 2000;86(12B):48M-52M.
13. Kelly J, Hunt BJ. Role of d-dimers in diagnosis of venous thromboembolism. Lancet 2002;359:456-8.
14. Kelly J, Rudd A, Lewis RR, et al. Plasma D-dimers in the diagnosis of venous thromboembolism. Arch Intern Med 2002;162:747-56.
15. Kearon C, Julian JA, Newman TE, et al. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 1998;128:663-77.
16. Fraser JD, Anderson DR. Deep venous thrombosis: recent advances and optimal investigation with U.S. Radiology 1999;211:9-24.
17. Rose SC, Zwiebel WJ, Nelson BD, et al. Symptomatic lower extremity deep venous thrombosis: accuracy, limitations and role of color duplex flow imaging in diagnosis. Radiology 1990;175:639-44.
18. Nilsson T, Carlsson A, Mare K. Pulmonary angiography: a safe procedure with modern contrast media and technique. Eur Radiol 1998;8:86-9.
19. Hudson ER, Smith TP, McDermott VG, et al. Pulmonary angiography performed with iopamidol: complications in 1,434 patients. Radiology 1996;198:61-5.
20. The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990;263:2753-9.
21. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest 1985;88:819-28.
22. Remy-Jardin M, Remy J, Deschildre F, et al. Diagnosis of pulmonary embolism with spiral CT: comparison with pulmonary angiography and scintigraphy. Radiology 1996;200:699-706.
23. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-83.
24. Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost 1997;78(suppl):141-4.
25. Johnson MJ. Problems of anticoagulation within a palliative care setting: an audit of hospice patients taking warfarin. Palliat Med 1997;11:306-12.
26. Lee AY, Levine M, et al. Low-molecular-weiqht heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.
27. Noble SIR, Finlay IG. Is long-term low molecular weight heparin an acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 2005;19:197-201.
28. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med 2002;162:1729-35.
29. Hull RD, Pineo GF, Mah AF, for the LITE Study Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062-72.
30. Monreal M, et al. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost 2004;2:1311-5.
31. British Thoracic Society. Guidelines for the management of suspected acute pulmonary embolism. Thorax 2003;58:470-84,
32. Noble SI, Hood K, Finlay IG. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of 62 patients. Palliat Med 2007;21:473-6.